New Single-Use Bag Film Lot and Operator Training Gap
A contract manufacturing organization is preparing to run a 1,000 L single-use bioreactor campaign in five days. The supplier has changed the film lot for the 1,000 L bag. The supplier's certificate of analysis states that extractables are below the compendial limit, but internal qualification requires three consecutive lots with extractables testing and a 14-day cell culture growth study. Only one new-lot bag has been tested internally: extractables were 0.6 mg/cm² against an internal action limit of 0.5 mg/cm², and the growth study is not complete. Six operators are trained on the bag installation procedure, but two records show training on revision A while the current procedure is revision B; revision B changed the inlet filter connection. The campaign schedule has no float. Quality can approve a deviation with a risk assessment. The product is a clinical-phase monoclonal antibody.
1. Should Quality approve the new bag lot for the campaign? Justify your answer using the qualification requirements and the extractables result.
Read the worked answer
Quality should not approve the new lot for routine use as though it were qualified. The internal qualification standard is explicit: three consecutive lots, extractables testing, and a 14-day growth study. Only one lot has been tested, the growth study is incomplete, and the extractables result of 0.6 mg/cm² exceeds the internal action limit of 0.5 mg/cm². The supplier's certificate of analysis does not substitute for the internal qualification, because it uses a compendial limit rather than the process-specific action limit and does not address cell culture effects.
A deviation could allow limited use only if the risk assessment is strong. It would need to identify the extractable species, estimate worst-case exposure in the 1,000 L culture, compare that exposure with a toxicological threshold, and include a concurrent growth and productivity study. The bag should also pass integrity and filter compatibility testing. Because the product is clinical-phase, the tolerance for unknown leachables is low. If those data cannot be generated in five days, the correct decision is to delay the campaign or use a qualified lot, not to treat the supplier CoA as sufficient.
2. How should the training-record gap be handled before the run?
Read the worked answer
The two operators trained on revision A should not independently perform the bag installation until they are trained and qualified on revision B. The change in the inlet filter connection is not a documentation-only change; it alters a critical connection that can affect sterility and flow path integrity.
The training should be completed before the campaign and should include a practical demonstration on a training bag, a review of the revised connection, and a signed qualification record. If the training cannot be completed in time, those operators can support the run only under direct supervision by a revision-B-qualified operator, and the deviation should document the restriction. The training gap should be treated as a separate deviation from the bag-lot issue, with its own risk assessment and completion date. A common failure mode is to let schedule pressure turn a training gap into an informal on-the-job briefing; that is not acceptable for a clinical campaign.
3. Draft a deviation and risk-assessment outline, including the specific tests and acceptance criteria you would require.
Read the worked answer
The deviation should state the unqualified film lot, the extractables excursion, the incomplete growth study, and the training gap. The risk assessment should evaluate patient impact, product quality, and schedule.
Required tests and acceptance criteria:
- Extractables identification and quantitation at worst-case contact time and temperature. Acceptance: no extractable above the internal action limit after accounting for dilution in the 1,000 L culture, and no unknown extractable above the toxicological threshold.
- 14-day cell culture growth study with the new lot. Acceptance: viability, growth rate, titer, and metabolite profile within the historical range for the qualified film lot.
- Bag integrity and filter compatibility after installation. Acceptance: no leak, no filter blockage, and pressure hold within specification.
- Leachables assessment at the harvest point. Acceptance: below the safety-based limit for the clinical dose.
- Training qualification records for all operators on revision B. Acceptance: practical sign-off before independent operation.
If any acceptance criterion is not met, the lot should not be used. The risk assessment should also include a fallback plan, such as using a qualified lot or delaying the campaign.